The effect of magnesium on plasma adiponectin and insulin resistance in first-degree relatives of diabetic patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105036296N2

Enrollment

Registered

2011-06-18

Start date

2010-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes melitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group will cosume 250 mg magnesium Oxide twice a day for 12 weeks. Intervention 2: Control group will receive nothing.

Treatment - Drugs

Lifestyle

Intervention group will cosume 250 mg magnesium Oxide twice a day for 12 weeks

Control group will receive nothing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion:First-degree relatives of diabetic patients with BMI >25kg/m2 exclusion:1Diabetic patients or first degree relatives with BMI=<25kg/m2 or who consumed Vit D or Zinc supplementation or metformin for past three months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Adiponectin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Adiponectin kit and the unit is ng/ml.;Insulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Insulin Kit and the Unit is mu/lit.	—

Secondary

Measure	Time frame
Fasting Blood Sugar. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyser method.;Total Cholestrol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Auto analyser method.;Triglycerid. Timepoint: 12 weeks. Method of measurement: Measurement of triglyceride by Auto Analyser method.;2 hour postprandial blood sugar. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyser method.;High Density Lipoprotein. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Auto analyser method.;Low Density Lipoprotein. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Auto analyser method.	—

Measure

Time frame

Fasting Blood Sugar. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyser method.;Total Cholestrol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Auto analyser method.;Triglycerid. Timepoint: 12 weeks. Method of measurement: Measurement of triglyceride by Auto Analyser method.;2 hour postprandial blood sugar. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyser method.;High Density Lipoprotein. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Auto analyser method.;Low Density Lipoprotein. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Auto analyser method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Babak majidi Dizaj

Yazd Diabetes Research Center

majidi_babak5@yahoo.com+98 912 290 4530

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026